Daniel Lopez-Trabada Ataz

Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial

Cindy Neuzillet, Olivier Bouché, Christophe Tournigand et al. · Journal of the National Comprehensive Cancer Network · 2023 · 27 citations · Full text

Medicine, Oncology, Cancer Rehabilitation +14

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study

Stéfano Kim, François Ghiringhelli, Christelle de la Fouchardière et al. · The Lancet Oncology · 2024 · 23 citations

Medicine, Oncology, Pharmacology +9

Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: A SCARCE-PRODIGE 60 randomized phase II study.

Stéfano Kim, François Ghiringhelli, Christelle de la Fouchardière et al. · Journal of Clinical Oncology · 2022 · 17 citations

Medicine, Oncology, Pharmacology +17

Adapted physical activity in patients (Pts) with advanced pancreatic cancer (APACaP): Results from a prospective national randomized GERCOR trial.

Cindy Neuzillet, Olivier Bouché, Christophe Tournigand et al. · Journal of Clinical Oncology · 2022 · 13 citations

Medicine, Oncology, Rehabilitation Medicine +17